Running Oak Capital LLC Sells 4,607 Shares of Becton, Dickinson and Company $BDX

Running Oak Capital LLC cut its position in Becton, Dickinson and Company (NYSE:BDX) by 5.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 85,963 shares of the medical instruments supplier’s stock after selling 4,607 shares during the period. Running Oak Capital LLC’s holdings in Becton, Dickinson and Company were worth $16,090,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. SOA Wealth Advisors LLC. grew its stake in Becton, Dickinson and Company by 256.8% in the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 95 shares during the period. Activest Wealth Management increased its holdings in Becton, Dickinson and Company by 285.3% during the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 97 shares in the last quarter. Bell Investment Advisors Inc grew its holdings in Becton, Dickinson and Company by 474.1% during the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 128 shares in the last quarter. Grey Fox Wealth Advisors LLC purchased a new stake in Becton, Dickinson and Company in the 3rd quarter valued at $32,000. Finally, Bank of Jackson Hole Trust lifted its stake in Becton, Dickinson and Company by 85.6% during the 2nd quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after acquiring an additional 95 shares in the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Trading Down 0.6%

NYSE:BDX opened at $202.29 on Tuesday. Becton, Dickinson and Company has a 12 month low of $162.29 and a 12 month high of $251.99. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69. The firm’s 50 day moving average is $198.76 and its 200 day moving average is $191.57. The stock has a market capitalization of $57.63 billion, a PE ratio of 34.70, a price-to-earnings-growth ratio of 2.25 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. The business had revenue of $5.89 billion during the quarter, compared to the consensus estimate of $5.91 billion. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%.The business’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same period last year, the business posted $3.81 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company announced that its board has initiated a share repurchase plan on Tuesday, January 27th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to repurchase up to 0% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be issued a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 annualized dividend and a yield of 2.1%. Becton, Dickinson and Company’s dividend payout ratio is 72.04%.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the transaction, the executive vice president directly owned 12,095 shares of the company’s stock, valued at approximately $2,509,228.70. This trade represents a 11.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bertram L. Scott sold 217 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the transaction, the director owned 35,816 shares of the company’s stock, valued at $6,324,389.28. This represents a 0.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 2,680 shares of company stock valued at $539,848 in the last quarter. Company insiders own 0.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on BDX shares. Piper Sandler upped their target price on shares of Becton, Dickinson and Company from $190.00 to $205.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 28th. Morgan Stanley increased their price objective on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research note on Tuesday, December 2nd. Stifel Nicolaus lifted their target price on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Royal Bank Of Canada lifted their price target on Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a report on Wednesday, December 17th. Four analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $209.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.